Preclinical modeling highlights the therapeutic potential of hematopoietic stem cell gene editing for correction of SCID-X1
Preclinical modeling highlights the therapeutic potential of hematopoietic stem cell gene editing for correction of SCID-X1 is a paper indexed in PICO Portal from OpenAlex.
How many citations does Preclinical modeling highlights the therapeutic potential of hematopoietic stem cell gene editing for correction of SCID-X1 have?
Preclinical modeling highlights the therapeutic potential of hematopoietic stem cell gene editing for correction of SCID-X1 has 217 citations in the OpenAlex counts PICO Portal stores.
When was Preclinical modeling highlights the therapeutic potential of hematopoietic stem cell gene editing for correction of SCID-X1 published?
Preclinical modeling highlights the therapeutic potential of hematopoietic stem cell gene editing for correction of SCID-X1 has 2017 year in the PICO Portal index.
What is the open-access status of Preclinical modeling highlights the therapeutic potential of hematopoietic stem cell gene editing for correction of SCID-X1?
Preclinical modeling highlights the therapeutic potential of hematopoietic stem cell gene editing for correction of SCID-X1 has closed oa status in the PICO Portal index.
What is the DOI of Preclinical modeling highlights the therapeutic potential of hematopoietic stem cell gene editing for correction of SCID-X1?
The DOI for Preclinical modeling highlights the therapeutic potential of hematopoietic stem cell gene editing for correction of SCID-X1 is on the source record.
What is the PMID of Preclinical modeling highlights the therapeutic potential of hematopoietic stem cell gene editing for correction of SCID-X1?
The PMID for Preclinical modeling highlights the therapeutic potential of hematopoietic stem cell gene editing for correction of SCID-X1 is on the source record.
What is the OpenAlex record for Preclinical modeling highlights the therapeutic potential of hematopoietic stem cell gene editing for correction of SCID-X1?
The OpenAlex for Preclinical modeling highlights the therapeutic potential of hematopoietic stem cell gene editing for correction of SCID-X1 is on the source record.